Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | PREP | P48147 | 4/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
| ▸ | F13A1 | P00488 | 1/20 | 0.30 |
| ▸ | TGM2 | P21980 | 1/20 | 0.30 |
| ▸ | TGM1 | P22735 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19296178 | 0.85 | CHRM2 (0.46) | CHRM2CHRM1CHRM3PREPNR1H2 | |
| SCHEMBL14899628 | 0.85 | CHRM2 (0.46) | CHRM2CHRM1CHRM3PREPNR1H2 | |
| SCHEMBL15996597 | 0.85 | CHRM2 (0.46) | CHRM2CHRM1CHRM3PREPNR1H2 | |
| SCHEMBL25510610 | 0.85 | CHRM2 (0.46) | CHRM2CHRM1CHRM3PREPNR1H2 | |
| SCHEMBL14229939 | 0.77 | CHRM2 (0.45) | CHRM2CHRM1CHRM3PREPNR1H2 | |
| SCHEMBL16004571 | 0.77 | CHRM2 (0.45) | CHRM2CHRM1CHRM3PREPNR1H2 | |
| SCHEMBL15580420 | 0.77 | CHRM2 (0.45) | CHRM2CHRM1CHRM3PREPNR1H2 | |
| SCHEMBL23153200 | 0.74 | CHRM2 (0.39) | CHRM2CHRM1CHRM3PREPNR1H2 | |
| SCHEMBL3442140 | 0.73 | CHRM2 (0.47) | CHRM2CHRM1CHRM3PREPNR1H2 | |
| SCHEMBL17598292 | 0.73 | CHRM2 (0.47) | CHRM2CHRM1CHRM3PREPNR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9724682-B2 | Synthesis of acyclic and cyclic amines using iron-catalyzed nitrene group transfer | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-08-08 | — | — | US | disclosed |
| US-20170072390-A1 | SYNTHESIS OF ACYCLIC AND CYCLIC AMINES USING IRON-CATALYZED NITRENE GROUP TRANSFER | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-03-16 | — | — | US | disclosed |
| US-9487472-B2 | Synthesis of acyclic and cyclic amines using iron-catalyzed nitrene group transfer | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-11-08 | — | — | US | disclosed |
| US-20160002145-A1 | SYNTHESIS OF ACYCLIC AND CYCLIC AMINES USING IRON-CATALYZED NITRENE GROUP TRANSFER | PRESIDENT AND FELLOWS OF HARVARD (US) | 2016-01-07 | — | — | US | disclosed |
| WO-2014134141-A1 | SYNTHESIS OF ACYCLIC AND CYCLIC AMINES USING IRON-CATALYZED NITRENE GROUP TRANSFER | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170072390-A1 | SYNTHESIS OF ACYCLIC AND CYCLIC AMINES USING IRON-CATALYZED NITRENE GROUP TRANSFER | FTH1, FLI1, FECH | CHRM2 3282/4885CHRM1 1776/4885CHRM3 3585/4885 |
| US-20160002145-A1 | SYNTHESIS OF ACYCLIC AND CYCLIC AMINES USING IRON-CATALYZED NITRENE GROUP TRANSFER | FTH1, FLI1, FECH | CHRM2 3282/4885CHRM1 1776/4885CHRM3 3585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.